Results 21 to 30 of about 24,454 (211)

Acromegaly [PDF]

open access: yesEndocrinology and Metabolism Clinics of North America, 2001
Acromegaly is a slow developing disease caused by hypersecretion of growth hormone and insulin-like growth factor 1. Increased morbidity and mortality associated with the disease make early diagnosis and treatment crucial. This article reviews the etiology, clinical manifestations, and diagnosis of acromegaly, with an emphasis on newly available ...
Anat, Ben-Shlomo, Shlomo, Melmed
openaire   +3 more sources

The acromegaly lipodystrophy

open access: yesFrontiers in Endocrinology, 2022
Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are essential to normal growth, metabolism, and body composition, but in acromegaly, excesses of these hormones strikingly alter them.
Pamela U. Freda
doaj   +1 more source

Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine [PDF]

open access: yesEndocrinology and Metabolism, 2023
The clinical characteristics and prognoses of acromegaly vary among patients. Assessment of current and novel predictors can lead to multilevel categorization of patients, allowing integration into new clinical guidelines and a reduction in the increased
Kyungwon Kim   +2 more
doaj   +1 more source

Prevalence and risk factors of sleep breathing disorders in patients with acromegaly from Moscow region [PDF]

open access: yesТерапевтический архив, 2018
Aim. Assessment of prevalence and risk factors of sleep breathing disorders in patients with acromegaly from Moscow region. Materials and methods. Cardiorespiratory monitoring was executed to 55 patients with acromegaly (18 men and 37 women): 27 patients
Yu A Kovaleva   +4 more
doaj   +1 more source

Ageing genetic signature of hypersomatotropism

open access: yesOpen Biology, 2021
Acromegaly is a pathological condition that is caused by over-secretion of growth hormone (GH) and develops primarily from a pituitary adenoma. Excess GH exposure over a prolonged period of time leads to a wide range of systemic manifestations and ...
Abdalla Elbialy
doaj   +1 more source

Old Wine in a New Bottle: Acromegaly Presenting as Diabetic Ketoacidosis [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2021
Acromegaly is a rare disease characterised by chronic excess of Growth Hormone (GH) levels. Insulin signalling is impaired, gluconeogenesis is excess and peripheral insulin resistance is increased in acromegaly causing hyperglycaemia and diabetes ...
Sowrabha Bhat   +3 more
doaj   +1 more source

Presence of cerebral microbleeds is associated with cognitive decline in acromegaly

open access: yesFrontiers in Oncology, 2022
BackgroundCognitive decline in acromegaly has gained increasing attention. Cerebral microbleeds (CMBs) as radiographic markers for microvascular injury have been linked to various types of cognitive decline. However, the association between CMB formation
Zhengxing Xie   +7 more
doaj   +1 more source

Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan

open access: yesFrontiers in Endocrinology, 2022
Acromegaly is a rare condition typically caused by benign pituitary adenomas, resulting in excessive production of growth hormone. Clinical manifestations of acromegaly are diverse, varying from the overgrowth of body tissue to cardiovascular, metabolic,
Marek Bolanowski   +17 more
doaj   +1 more source

Acromegaly [PDF]

open access: yesQJM: An International Journal of Medicine, 2016
Abstract Acromegaly is a rare, chronic, progressive disease characterized by an excess secretion of growth hormone (GH) and increased circulating insulin-like growth factor 1 (IGF-1) concentrations. It is caused by a pituitary adenoma in the vast majority of cases.
R, Dineen, P M, Stewart, M, Sherlock
openaire   +2 more sources

Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study

open access: yesBiomedicines, 2023
Acromegaly is a rare endocrine disorder caused by somatotroph pituitary adenoma. Besides its typical symptoms, it contributes to the development of cardiovascular, metabolic, and bone comorbidities. H19 RNA is a long non-coding RNA and it is suspected to
Małgorzata Rolla   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy